Floatz logo

Cea-Targeted Car-T

Solid Cancers

Weijia Fang, MDCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the Solid Cancers cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Genentech, Inc.
Phase 2B
(+)-VINCRISTINE
Hoffmann-La Roche
Phase 1B
Irinotecan
Hoffmann-La Roche
Phase 1B
Tunlametinib
Tianjin Medical University Second Hospital
Phase 2CCC
PARSATUZUMAB
Genentech, Inc.
Phase 1CCC

View all 49 →

Same molecule, other indications

Cea-Targeted Car-T is also rated in:

rectal carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
malignant pancreatic neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
gastric cancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →